{"DataElement":{"publicId":"3553260","version":"1","preferredName":"Response Assessment Myeloma Status Category","preferredDefinition":"Text term to define the result of myeloma after therapeutic intervention/treatment.","longName":"RESP_ASSESS_MYL_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2012676","version":"3","preferredName":"Response Assessment","preferredDefinition":"Evaluation of a change in the condition under investigation.","longName":"RESPS_ASSESS","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2177008","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AD5-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2178813","version":"1","preferredName":"Assessment","preferredDefinition":"The final result of a determination of the value, significance, or extent of.","longName":"Assessment","context":"CCR","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE26673C-624D-3309-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-11","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Added Concept Code AA","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A56E9E7B-DAEE-1DF9-E034-080020C9C0E0","latestVersionIndicator":"Yes","beginDate":"2002-07-10","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3553258","version":"1","preferredName":"Plasma Cell Myeloma Disease Status Category","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Status; a condition or state at a particular time._Category; used informally to mean a class of things.","longName":"3553258v1.0","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Refractory disease","valueDescription":"Multiple Myeloma refractory disease","ValueMeaning":{"publicId":"3553259","version":"1","preferredName":"Multiple Myeloma refractory disease","longName":"3553259","preferredDefinition":"Unresponsiveness to current therapy or progressive disease within 60 days of prior treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6BFBB7F-4856-518F-E040-BB89AD431BA0","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-486F-518F-E040-BB89AD431BA0","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Complete response","valueDescription":"Complete Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"3541528","version":"1","preferredName":"Complete Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"3541528","preferredDefinition":"Complete response of multiple myeloma or plasma cell leukemia is characterized by negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and less than 5% plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). Complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy complete response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70639","definition":"Complete response of multiple myeloma or plasma cell leukemia is characterized by negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and less than 5% plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). Complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy complete response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C661F4F8-E093-BB1A-E040-BB89AD436C64","latestVersionIndicator":"Yes","beginDate":"2012-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-4879-518F-E040-BB89AD431BA0","beginDate":"2009-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Partial response","valueDescription":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691337","version":"1","preferredName":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691337","preferredDefinition":"Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70641","definition":"Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-4320-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Removed and then added the concept due to definition change in NCIt. mc 11/11/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-4883-518F-E040-BB89AD431BA0","beginDate":"2009-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progression of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691336","version":"1","preferredName":"Progression of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691336","preferredDefinition":"Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progression of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70643","definition":"Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-42F9-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Removed and added back concept to update definition to latest NCIt. mc 11/11/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-488D-518F-E040-BB89AD431BA0","beginDate":"2009-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Relapse from CR","valueDescription":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691335","version":"1","preferredName":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691335","preferredDefinition":"Relapse from complete response of multiple myeloma or plasma cell leukemia requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of 5% or more plasma cells in the bone marrow (relapse from complete response has a 5% cutoff vs.10% for other categories of relapse); appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70645","definition":"Relapse from complete response of multiple myeloma or plasma cell leukemia requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of 5% or more plasma cells in the bone marrow (relapse from complete response has a 5% cutoff vs.10% for other categories of relapse); appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-42D2-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-4897-518F-E040-BB89AD431BA0","beginDate":"2009-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Stable disease","valueDescription":"Stable Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"3541529","version":"1","preferredName":"Stable Multiple Myeloma or Plasma Cell Leukemia","longName":"3541529","preferredDefinition":": Stable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70642","definition":"Stable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C661F4F8-E0F2-BB1A-E040-BB89AD436C64","latestVersionIndicator":"Yes","beginDate":"2012-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-48A1-518F-E040-BB89AD431BA0","beginDate":"2009-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Stringent complete response","valueDescription":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2982983","version":"1","preferredName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","longName":"2982983","preferredDefinition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70637","definition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0123-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-48AC-518F-E040-BB89AD431BA0","beginDate":"2009-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3241403","version":"1","preferredName":"Unknown","longName":"3241403","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A3A-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"MMADDINENI","dateModified":"2023-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-48B6-518F-E040-BB89AD431BA0","beginDate":"2011-11-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Very good partial response","valueDescription":"Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"3541530","version":"1","preferredName":"Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"3541530","preferredDefinition":"Very good partial response of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours.  Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70638","definition":"Very good partial response of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours. Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C661F4F8-E11E-BB1A-E040-BB89AD436C64","latestVersionIndicator":"Yes","beginDate":"2012-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6BFBB7F-48C1-518F-E040-BB89AD431BA0","beginDate":"2009-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3553257","version":"1","preferredName":"Plasma Cell Myeloma Disease or Disorder Status Category","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001):Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Status; a condition or state at a particular time.:Category; used informally to mean a class of things.","longName":"C3242:C2991:CL052713:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"CL052713","definition":"Status; a condition or state at a particular time.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6BFBB7F-482F-518F-E040-BB89AD431BA0","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6BFBB7F-4840-518F-E040-BB89AD431BA0","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"REEVESD","dateModified":"2012-08-08","changeDescription":"VD uses permissible values from NMDP VD 2950502, which is modeled on the international standard for myeloma response criteria with the additional permissible value of 'refractory disease'.  Created for NCI CCR clinical trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Response Assessment","type":"Preferred Question Text","description":"Response Assessment","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6BFBB7F-48CB-518F-E040-BB89AD431BA0","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"REEVESD","dateModified":"2012-08-13","changeDescription":"Curated to support NCI CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}